医学
真皮
粘液水肿
病因学
皮肤病科
皮下脂肪
水肿
甲状腺
病理
内科学
脂肪组织
作者
Abigail Washington,Hannah Nam,Michelle Pitch,Bryan Anderson,Jennifer Stokes,Matthew Helm
出处
期刊:Journal of Drugs in Dermatology
[SanovaWorks]
日期:2022-10-01
卷期号:21 (11): 1252-1254
摘要
Pretibial myxedema (PTM) is a rare complication of Graves' disease. It is characterized by non-pitting edema with hyperpigmented hyperkeratotic papules and plaques on bilateral lower legs. Effective treatments for patients with PTM are lacking. The etiology of PTM is unknown; however, it may be similar to the mechanism of thyroid-associated ophthalmopathy (TAO). Activated fibroblasts produce inflammatory cytokines and synthesize excessive glycosaminoglycans (GAG) that accumulate in the dermis and subcutaneous tissue. A recent, novel pathway implicates IGF-1 receptor as a mediator in this process. We present two patients with refractory PTM that improved following treatment with teprotumumab, an IGF-1 receptor inhibitor approved for use in TAO. J Drugs Dermatol. 2022;21(11):1252-1254. doi:10.36849/JDD.6854.
科研通智能强力驱动
Strongly Powered by AbleSci AI